Abstract:The current research is aimed at formulation and in-vivo evaluation of dasatinib solid lipid nanoparticles (SLN) for enhanced solubility and bioavailability. A 33 Box-Behnken design (BBD) was used to optimize the formulations in which amount of glycerol monosterate(X1) the amount of poloxamer 407 (X2) and amount of tyloxopol (X3) were chosen as independent variables while particle size, entrapment efficiency and drug release after 12 hours were chosen as dependent variables. About 17 SLN formulations of dasatinib were prepared using glyceryl monostearate, poloxamer 407, Tyloxopol and Tween 80 and optimised using desirability function. All the SLNs were evaluated for fourier transform infrared spectroscopy (FTIR), particle size, zeta potential, entrapment efficiency and drug release behavior were investigated. The in-vivo pharmacokinetic evaluation of opimised SLN was carried out in rats. Based on BBD and desirability function the formulation comprising of X1:10, X2:06 and X3:02 was chosen optimal. The model was proven to be validated since a fine agreement existed between the predicted and observed results. It can be seen that the experimental values were in very close agreement with the predicted values, indicating the success of the BBD combined with a desirability function for the evaluation and optimization of SLNs formulations. The formulation DF10 displayed a mean particle size of 112 nm with PI of 0.40 and zeta potential of −25.6 mV.The in-vitro release studies showed that more than 98.78% of drug was released from optimized SLN after 12 hours, which is higher when compared with marketed formulation. The release kinetics of the optimized formulation followed zero order drug release and best fitted the Korsemeyer-peppas model. At any time, point, the drug plasma concentrations in animals administrated with optimized SLN was higher than that of pure drug. Cmax of the dasatinib optimised SLN 158.26 ± 0.54 ng/mL was significant (p < 0.05) as compared to the pure drug suspension formulation 32.08 ± 0.21 ng/mL. Tmax of both optimised SLN formulation and pure drug was 1.0 ± 0.47 and 1.0 ± 0.04 hour, respectively AUC0-∞ infinity for dasatinib optimised SLN formulation was higher (702.23 ± 1.26 ng.h/mL) than the pure drug suspension 191.67 ± 1.27 ng.h/mL. Statistically, AUC0-t of the optimised SLN formulation was significantly higher (p < 0.05) as compared to pure drug suspension formulation. These results indicated that the dasatinib-loaded SLN formulation could potentially be exploited for the treatment of chronic myelogenous leukemia with controlled release manner.

Investigating the effect of polyvinylpyrrolidone matrix on surface characteristics and dissolution rate of anticancer drug dasatinib

Polymeric Amorphous Solid Dispersions of Dasatinib: Formulation and Ecotoxicological Assessment

Facile fabrication of dasatinib laden multifunctional polymeric micelles: Evaluation of anti‐proliferative and apoptotic activities in human cancer cells

Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform

Dasatinib loaded mucoadhesive lecithin-chitosan hybrid nanoparticles for its augmented oral delivery, in-vitro efficacy and safety

Advancing Drug Delivery Paradigms: Polyvinyl Pyrolidone (PVP)-Based Amorphous Solid Dispersion for Enhanced Physicochemical Properties and Therapeutic Efficacy

Supersaturable diacyl phospholipid dispersion for improving oral bioavailability of brick dust molecule: A case study of Aprepitant

Manifesting the Dasatinib-gallic acid co-amorphous system to augment anticancer potential: Physicochemical characterization, in silico molecular simulation, ex vivo permeability, and in vitro efficacy

Preparation, Characterization and Evaluation of Nintedanib Amorphous Solid Dispersions with Enhanced Oral Bioavailability

Effect of Drug–Polymer Interaction in Amorphous Solid Dispersion on the Physical Stability and Dissolution of Drugs: The Case of Alpha-Mangostin

Formulation and In-vivo Evaluation of Dasatinib-loaded Solid Lipid Nanoparticles

Improving Tumor Specificity and Anticancer Activity of Dasatinib by Dual-Targeted Polymeric Micelles.

Unraveling the Influence of Solvent Composition on Drop-on-Demand Binder Jet 3D Printed Tablets Containing Calcium Sulfate Hemihydrate

The preparation and physicochemical characterization of eprosartan mesylate-laden polymeric ternary solid dispersions for enhanced solubility and dissolution rate of the drug

Physicochemical characterisation, drug polymer dissolution and in vitro evaluation of phenacetin and phenylbutazone solid dispersions with polyethylene glycol 8000

Polymer Selection for Amorphous Solid Dispersion of a New Drug Candidate by Investigation of Drug Polymer Molecular Interactions.

Drug-polymer-water interaction and its implication for the dissolution performance of amorphous solid dispersions.

Impact of HPMCAS on the Dissolution Performance of Polyvinyl Alcohol Celecoxib Amorphous Solid Dispersions

Dasatinib self-assembled nanoparticles decorated with hyaluronic acid for targeted treatment of tumors to overcome multidrug resistance

ENHANCED SOLUBILITY AND DISSOLUTION BY SURFACE-MODIFIED SOLID DISPERSION OF ALECTINIB HYDROCHLORIDE

Binary polymeric amorphous carvedilol solid dispersions: In vitro and in vivo characterization